文献速递类风湿关节炎

JAK抑制剂对类风湿关节炎患者心血管事件风险的影响:随机对照试验的系统综述与Meta分析

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
PubMed 文献 · Ann Rheum Dis · 2019-05-14

总体未发现全因心血管事件、主要不良心血管事件或静脉血栓栓塞事件风险显著增加,但巴瑞替尼2mg较4mg在全因心血管事件上更安全,高剂量托法替布和巴瑞替尼的血栓栓塞风险仍需上市后数据确认。

要点

  • JAK抑制剂总体未显著增加全因心血管事件、MACE或VTE风险。
  • 巴瑞替尼2mg较4mg在全因心血管事件发生率上更安全。
  • 高剂量托法替布和巴瑞替尼的血栓栓塞风险需上市后数据确认。

核心结论

  • 现有RCT证据表明JAK抑制剂短期治疗类风湿关节炎患者未显著改变心血管风险。
  • 因高剂量托法替布和巴瑞替尼增加血栓栓塞事件风险,亟需上市后数据明确心血管安全性。

研究设计与样本

  • 系统检索PubMed、Embase和Cochrane图书馆从建库至2018年10月的RCT。
  • 采用Mantel-Haenszel固定效应法计算OR和95%CI。

主要发现

  • JAK抑制剂总体全因心血管事件风险无显著差异(OR 1.04,95%CI 0.61-1.76,p=0.89)。
  • 托法替布(OR 0.63,95%CI 0.26-1.54,p=0.31)、巴瑞替尼(OR 1.21,95%CI 0.51-2.83,p=0.66)、乌帕替尼(OR 3.29,95%CI 0.59-18.44,p=0.18)、培非替尼(OR 0.43,95%CI 0.07-2.54,p=0.35)、decernotinib(OR 1.12,95%CI 0.13-10.11,p=0.92)的全因心血管事件风险均无显著差异。
  • JAK抑制剂总体MACE风险无显著差异(OR 0.80,95%CI 0.36-1.75,p=0.57),VTE风险无显著差异(OR 1.16,95%CI 0.48-2.81,p=0.74)。
  • 巴瑞替尼2mg较4mg在全因心血管事件发生率上更安全(OR 0.19,95%CI 0.04-0.88,p=0.03)。
  • 托法替布5mg与10mg、乌帕替尼15mg与30mg之间未观察到全因心血管事件、MACE和VTE风险的剂量依赖性影响。

关键数值与推荐

  • 主要结局为全因心血管事件,次要结局为MACE和VTE。
  • JAK抑制剂总体全因心血管事件OR 1.04(95%CI 0.61-1.76,p=0.89)。
  • JAK抑制剂总体MACE OR 0.80(95%CI 0.36-1.75,p=0.57),VTE OR 1.16(95%CI 0.48-2.81,p=0.74)。
  • 巴瑞替尼2mg vs 4mg全因心血管事件OR 0.19(95%CI 0.04-0.88,p=0.03)。

临床怎么用

  • 短期使用JAK抑制剂时总体心血管风险未见显著增加,但应关注高剂量托法替布和巴瑞替尼的血栓栓塞风险。
  • 巴瑞替尼2mg可能较4mg在全因心血管事件方面更安全,临床决策时可考虑剂量选择。

局限性

  • 证据仅来自短期RCT,需上市后数据进一步确认心血管安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the effect of Janus kinase inhibitors (Jakinibs) on cardiovascular risk in adult patients with rheumatoid arthritis (RA) via a meta-analysis of randomised controlled trials (RCTs). METHODS: PubMed, Embase and Cochrane library were thoroughly searched for RCTs reporting safety issues in patients with RA receiving Jakinibs, from inception to October 2018. The primary and secondary outcomes were all cardiovascular events (CVEs) and major adverse cardiovascular events (MACEs)/venous thromboembolism events (VTEs). OR and 95% CI were calculated using the Mantel-Haenszel fixed-effect method. RESULTS: 26 RCTs randomising 11 799 patients were included. No significant difference was observed regarding all CVEs risk following Jakinibs usage in general (OR 1.04 (0.61 to 1.76), p = 0.89), tofacitinib (OR 0.63 (0.26 to 1.54), p = 0.31), baricitinib (OR 1.21 (0.51 to 2.83), p = 0.66), upadacitinib (OR 3.29 (0.59 to 18.44), p = 0.18), peficitinib (OR 0.43 (0.07 to 2.54), p = 0.35) or decernotinib (OR 1.12 (0.13 to 10.11), p = 0.92). Likewise, there was no significant difference for Jakinibs treatment overall regarding occurrence of MACEs (OR 0.80 (0.36 to 1.75), p = 0.57) or VTEs (OR 1.16 (0.48 to 2.81), p = 0.74). Dose-dependent impact of Jakinibs on the risks of all CVEs, MACEs and VTEs was not observed in tofacitinib (5 mg vs 10 mg), upadacitinib (15 mg vs 30 mg), whereas baricitinib at 2 mg was found to be safer than 4 mg in all CVEs incidence (OR 0.19 (0.04 to 0.88), p = 0.03). CONCLUSION: The existing evidence from RCTs indicated no significant change in cardiovascular risk for Jakinib-treated patients with RA in a short-term perspective, but postmarketing data are sorely needed to ascertain their cardiovascular safety, especially at the higher dose, due to increased risk of thromboembolism events for both tofacitinib and baricitinib at higher dosage.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019. PMID: 31088790. doi:10.1136/annrheumdis-2018-214846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。